Discontinued — last reported Q2 '24

Other

Unrealized Gains on Available-for-Sale Securities

Analysis

StatementIncome Statement
SectionOther
First reportedQ1 2018
Last reportedQ2 2024
Metric ID: isrg_unrealized_gains_on_available_for_sale_securities

Historical Data

13 periods
 Q2 '21Q3 '21Q1 '22Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q1 '26
Value-$500.00K$100.00K-$9.70M-$8.30M-$1.00M$5.70M-$4.50M$14.50M$0.00$0.00$0.00$0.00-$1.80M
QoQ Change+120.0%<-999%+14.4%+88.0%+670.0%-178.9%+422.2%-100.0%
YoY Change<-999%<-999%+158.8%+45.8%>999%-100.0%+100.0%-100.0%
Range-$9.70M$14.50M
CAGR+53.3%
Avg YoY Growth-125.7%
Median YoY Growth-27.1%

Frequently Asked Questions

What is Biogen's unrealized gains on available-for-sale securities?
Biogen (BIIB) reported unrealized gains on available-for-sale securities of -$1.80M in Q1 2026.